Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ACP-103: Phase Ib/IIa data

In a double-blind, placebo-controlled U.S. Phase Ib/IIa trial in 12 patients, ACP-103

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE